TORONTO, ON / ACCESSWIRE / April 3, 2014 / Theralase Technologies Inc. ("Theralase") (TSXV: TLT) (TLTFF: OTCBB) announced today that it has advanced its anti-cancer technology platform through an executed research agreement with Acadia University ("Acadia"). Under the terms of the agreement, Acadia will supply initial quantities of Theralase's lead Photo Dynamic Compounds (PDCs) and the Standard Operating Procedures (SOPs) of how to synthesize them.
The lead PDCs will be used by Theralase to commence toxicity analysis and manufacturing ramp up via Contract Manufacturing Organization (CMO); both mandatory prerequisites in the evolution towards an approved Investigational New Drug (IND) application from the FDA and Health Canada. With larger quantities of the PDCs in hand and an approved IND; Theralase would be in the position to commence a Phase 1/2a human clinical trial for the lead indication of bladder cancer, as early as 1Q2015.
The lead PDCs have advanced towards international patent protection under a filed Patent Cooperation Treaty (PCT) application. Once approved at this phase, the Company plans to provide wide spread patent coverage of the PDCs across numerous countries during the national phase.
Dr. Sherri McFarland, Professor of Chemistry at Acadia University, the originator of the PDCs under worldwide exclusive licence to Theralase stated, "I am truly excited to work with Theralase in the development of these PDCs and be associated with their lead scientists and clinical oncologists to develop the next generation of anti-cancer technology. From the raw research I have observed, this technology has the potential to not only destroy one type of cancer, but many. I am convinced that this technology has the opportunity to go mainstream as a primary treatment in the destruction of cancer, within the next few years."
Dr. David MacKinnon, Dean, Research and Graduate Studies at Acadia University stated, "We are pleased to have partnered with Theralase in the development of these PDCs for the destruction of cancer. It is rewarding to advance research originally developed in our chemistry labs from conception through to commercialization knowing that it may one day be a cure for cancer."
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated that, "Sherri's strong background as a medicinal chemist and specialist in photochemistry, coupled with my scientific and medical knowledge as to how laser light interacts at the molecular and cellular level, will bring a new platform of cutting-edge anti-cancer technologies to the forefront within the next few years."
Roger Dumoulin-White, President and CEO of Theralase stated that, "I am delighted that Acadia has partnered with Theralase in the commercialization of technology that may provide a new front line treatment for cancer in the not too distant future. With good partners, disruptive technologies are born, which can make marked impacts on devastating diseases such as cancer, in our lifetime. I am humbled to be part of the process."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint injuries. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated.
Additional information is available at www.theralase.com and www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
Theralase Technologies Inc.
416.699.LASE (5273) ext. 225
Dean, Research and Graduate Studies
SOURCE: Theralase Technologies Inc.
Leave a comment...